These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer. Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479 [TBL] [Abstract][Full Text] [Related]
11. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794 [TBL] [Abstract][Full Text] [Related]
12. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients. Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539 [TBL] [Abstract][Full Text] [Related]
13. Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients. Kusada T; Toita T; Ariga T; Kudaka W; Maemoto H; Makino W; Ishikawa K; Heianna J; Nagai Y; Aoki Y; Murayama S Int J Clin Oncol; 2020 Nov; 25(11):1977-1984. PubMed ID: 32852648 [TBL] [Abstract][Full Text] [Related]
14. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448 [TBL] [Abstract][Full Text] [Related]
15. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia. Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594 [TBL] [Abstract][Full Text] [Related]
16. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K; Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262 [TBL] [Abstract][Full Text] [Related]
17. Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer. Refaat T; Castelain B; Small W; Elsaid A; Lotfy N; Lartigau E; Nickers P Am J Clin Oncol; 2015 Jun; 38(3):289-93. PubMed ID: 23799285 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer. Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK Tumori; 2012; 98(5):615-21. PubMed ID: 23235757 [TBL] [Abstract][Full Text] [Related]
20. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes. Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]